Curis (CRIS) Stock Forecast & Price Target

Curis is supported by a strengthening emavusertib dataset in PCNSL, where the BTKi-naïve cohort showed a 100% ORR in five of five evaluable patients and the broader BTKi-naïve group reached 86% across seven patients, while the BTKi-experienced cohort improved to 33% in 30 evaluable patients. Management’s regulatory feedback indicating potential accelerated approval in the U.S. and Conditional Marketing Authorization in Europe enhances the commercial and strategic value of the program, which represents 56% of the modeled valuation, while the TakeAim CLL study adds another avenue for upside through dual NF-κB blockade and deeper responses. Although Curis remains financially constrained with $5.07 million in cash at quarter-end and only enough liquidity, including recent offering proceeds, to fund operations into 4Q26, the advancing clinical execution and expanding patient base suggest meaningful fundamental upside if additional capital is secured.

Curis is facing a weak fundamental setup because the all-patients ORR in the BTKi-experienced cohort, which underpins the accelerated approval path, was only 26% (10 of 39) on the July 1, 2026 cut, barely changed from 27% (7 of 26) as of May 1, 2025 despite a 50% larger cohort. The fact that 23% of patients failed to complete at least one 28-day cycle, while the reported 33% evaluable ORR excludes those early discontinuations, raises durability and tolerability concerns and makes the headline efficacy less compelling on a registrational basis. Although TakeAim CLL enrollment is ahead of plan with consented patients rising to 10 and year-end guidance raised to 5-10 patients, the company remains highly dependent on a small, noisy dataset and a December readout for near-term value creation.